Study Finds Abelacimab Effective against Blood Clot

Aug, 2021 - By SMI

A team of researchers from McMaster University, Canada revealed that a new treatment has been developed for people with or at risk of blood clots.

The researchers considered 412 individuals who underwent knee replacement surgery. In this study, the researchers analyzed the drugs abelacimab and enoxaparin in these 412 patients. They found that one abelacimab injection can prevent blood clots for up to a month following surgery. Abelacimab is a monoclonal antibody that has the potential to prevent clotting of blood. Abelacimab binds to both activated and inactivated clotting factor known as factor XI.  The researchers revealed that the clotting factor XI plays a key role in clot formation after surgery. This result is significant in comparison to enoxaparin as an abelacimab injection reduce the risk of bleeding up to 80%. In this context, it is important to mention that patients undergoing knee replacement surgery receive anti-clotting treatment with enoxaparin. These patients are administered enoxaparin or other anticoagulant medications daily. Moreover, the researchers closely monitored those patients considered for the study for any sign of clotting or bleeding. They even conducted an x-ray to detect if any clot had formed in the veins of the operated leg. The researchers revealed that abelacimab could be a better option and abelacimab can provide better protection against clots in the veins in comparison to enoxaparin. The researchers added that different doses of abelacimab can be examined in patients undergoing knee replacement surgery to choose which dose would be safe and effective in comparison to current standard of care such as enoxaparin.

Taken together, the researchers concluded that the findings of this study shed light on the foundation of the use of abelacimab in preventing stoke in individuals suffering from atrial fibrillation, deep-vein thrombosis, and pulmonary embolism. The researchers are optimistic about the use of abelacimab in patients with cancer as well.